Pharmacokinetics of Ertapenem in Sheep (Ovis aries) with Experimentally Induced Urinary Tract Infection Plummer, Paul Smith, Joe Smith, Joe Borts, David Slagel, Clare Rajewski, Suzanne Mochel, Jonathan Bousquet‑Melou, Alain Ferran, Aude Plummer, Paul Mochel, Jonathan
dc.contributor.department Biomedical Sciences
dc.contributor.department Veterinary Microbiology and Preventive Medicine
dc.contributor.department Veterinary Diagnostic and Production Animal Medicine 2019-10-25T19:19:17.000 2020-07-07T05:12:59Z 2020-07-07T05:12:59Z Tue Jan 01 00:00:00 UTC 2019 2019-10-01
dc.description.abstract <p>Sheep are commonly used as animal models for human biomedical research, but descriptions of their use for studying the pharmacokinetics of carbapenem antimicrobials, such as ertapenem, are unavailable. Ertapenem is a critical antimicrobial for human infections, and the description of the pharmacokinetics of this drug is of value for research using ovine as models for human diseases, such as urinary tract infections (UTI). There are currently no ovine models for comparative biomedical research of UTI. The objective of this study was to report the pharmacokinetics of ertapenem in sheep after single and multiple dosing. In addition, we explored the effects of an immunomodulatory drug (Zelnate) on the pharmacokinetics of ertapenem in sheep. Eight healthy ewes (weight, 64.4 ± 7.7 kg) were used in an ovine bacterial cystitis model of human cystitis with <em>Pseudomonas aeruginosa</em>. After disease confirmation, each ewe received 1 g of ertapenem intravenously once every 24 h for 5 administrations. Blood was collected intensively (14 samples) during 24 h after the first and last administration. After multiple-dose administration, the volume of distribution was 84.5 mL/kg, clearance was 116.3 mL/h/kg, T1/2(λz) was 1.1 h, and the extraction ratio was 0.02. No significant differences in pharmacokinetic parameters or time points were found between groups treated with the immunostimulant and controls or after the 1st or 5th administration of ertapenem. No accumulation was noted from previous administration. Our ovine pharmacokinetic findings can be used to evaluate therapeutic strategies for ertapenem use (varying drug dosing schedules and combinations with other antimicrobials or immune modulators) in the context of UTI.</p>
dc.description.comments <p>This article is published as Smith, Joe S., David J. Borts, Clare C. Slagel, Suzanne M. Rajewski, Alain Bousquet-Melou, Aude A. Ferran, Paul J. Plummer, and Jon P. Mochel. "Pharmacokinetics of Ertapenem in Sheep (<em>Ovis aries</em>) with Experimentally Induced Urinary Tract Infection." <em>Comparative Medicine</em> 69, no. 5 (2019): 413-418. DOI: <a href="" target="_blank">10.30802/AALAS-CM-18-000144</a>. Posted with permission.</p>
dc.format.mimetype application/pdf
dc.identifier archive/
dc.identifier.articleid 1164
dc.identifier.contextkey 15623880
dc.identifier.s3bucket isulib-bepress-aws-west
dc.identifier.submissionpath vdpam_pubs/160
dc.language.iso en
dc.source.bitstream archive/|||Fri Jan 14 20:53:43 UTC 2022
dc.source.bitstream archive/|||Fri Jan 14 20:53:45 UTC 2022
dc.source.uri 10.30802/AALAS-CM-18-000144
dc.subject.disciplines Large or Food Animal and Equine Medicine
dc.subject.disciplines Veterinary Infectious Diseases
dc.title Pharmacokinetics of Ertapenem in Sheep (Ovis aries) with Experimentally Induced Urinary Tract Infection
dc.type article
dc.type.genre article
dspace.entity.type Publication
relation.isAuthorOfPublication f16d5130-7036-437d-892d-b4a4072903e7
relation.isAuthorOfPublication 0959860b-5308-482e-89f6-3e6882344a3b
relation.isAuthorOfPublication a34180b7-6b71-4b6f-a08d-5a53c5122d9b
relation.isOrgUnitOfPublication 184db3f2-d93f-4571-8ad7-07c8a9e6a5c9
relation.isOrgUnitOfPublication 16f8e472-b1cd-4d8f-b016-09e96dbc4d83
relation.isOrgUnitOfPublication 5ab07352-4171-4f53-bbd7-ac5d616f7aa8
Original bundle
Now showing 1 - 2 of 2
154.87 KB
Adobe Portable Document Format
100.58 KB
Adobe Portable Document Format